Mandate

Vinge advises the shareholders of OptiGroup AB in connection with the divestment to FSN Capital

Vinge advises the shareholders of OptiGroup AB in connection with the divestment of a majority shareholding to FSN Capital. Current majority shareholders Triton, Altor and RoosGruppen will retain a minority holding in the company.

Headquartered in Mölndal, Sweden, OptiGroup is a leading European distribution group with presence in 16 countries that provides customised supply solutions to more than 90,000 B2B customers. The companies in the group’s three business areas Facility, Safety & Foodservice, Packaging and Paper and Business Supplies offer reliable and sustainable supply solutions for players in the cleaning and facility management, hotel and restaurant, health and medical care, manufacturing industry and the graphic sector.

The transaction is subject to applicable competition law approvals.

Vinge’s team consisted of Christina Kokko, Johanna Wiberg, Elsie Nassar, Nando Basic and Egil Svensson (M&A), Jolinn Uhlin (Banking and Finance), Isabell Nielsen and Mario Saad (Commercial Agreements), Gustav Lindgren (Employment), Mathilda Persson and Martin Boström (IT), Karl-Hugo Engdahl (GDPR), Sofia Bergenstråhle (Intellectual Property), Kristoffer Larson (Real Property), Lina Österberg (Environmental Law), Tove Lövgren Frisk (Compliance) and Viktoria Owetz (VDR Specialist) and Jasmina Skandrani (Project Assistant).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025